Table 3.

Therapeutic management of TMA patients.

Treatment, n (%)		Primary TMA		Secondary TMA
	All	TTP	aHUS	tHUS	HELLP syndrome	Malignant HBP	Malignancies	Drugs	Infections	AID	aGVHD	Others
	n = 216	n = 12	n = 8	n = 8	n = 79	n = 12	n = 30	n = 11	n = 5	n = 5	n = 16	n = 30
Plasma exchange	40 (18.5)	9 (75.0)	6 (75.0)	6 (75.0)	0 (0)	1 (8.3)	5 (16.6)	3 (27.3)	2 (40.0)	3 (60.0)	1 (6.25)	4 (13.3)
Plasma infusion	30 (13.9)	2 (16.6)	2 (25.0)	2 (25.0)	10 (12.7)	0 (0)	3 (10.0)	3 (27.3)	0 (0)	0 (0)	2 (12.5)	6 (20.0)
PE or PI	61 (28.2)	9 (75.0)	6 (75.0)	6 (75.0)	10 (12.7)	1 (8.3)	6 (20.0)	6 (54.5)	2 (40.0)	3 (60.0)	3 (18.8)	9 (30.0)
Eculizumab	8 (3.7)	1 (8.3)	3 (37.5)	2 (20.0)	0 (0)	0 (0)	1 (3.3)	1 (9.1)	0 (0)	0 (0)	0 (0)	0 (0)
Rituximab	17 (7.9)	6 (50.0)	1 (12.5)	0 (0)	0 (0)	0 (0)	3 (10.0)	0 (0)	0 (0)	2 (40.0)	4 (25.0)	1 (3.3)
Red blood cell transfusion	94 (43.5)	8 (66.7)	4 (50.0)	4 (50.0)	14 (17.7)	6 (50.0)	19 (63.3)	5 (45.4)	2 (40.0)	4 (80.0)	15 (93.8)	13 (43.3)
Platelet transfusion	49 (22.7)	3 (25.0)	1 (12.5)	1 (12.5)	7 (8.9)	1 (8.3)	12 (40.0)	5 (45.4)	0 (0)	0 (0)	14 (87.5)	5 (16.6)
Dialysis (during first admission)	51 (23.6)	3 (25.0)	6 (75.0)	3 (37.5)	6 (7.59)	10 (83.3)	5 (16.7)	3 (27.3)	3 (60.0)	2 (40.0)	2 (12.5)	8 (26.7)